company-logoTourmaline Bio, Inc.$47.85
%
Analyst Rating: Hold

Stock Details

CEO

Sandeep C. Kulkarni

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

74

Address

27 West 24th Street, New York City, NY, 10010

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Top Competitors

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Tourmaline Bio, Inc.  $47.85

EPS

Revenue

Institutional Holder

Congress Tracker 

Insider Trading of Key Employees

Financial News: TRML